Ginger in fatty liver disease with type 2 diabetes: what a clinical trial shows

The clearest practical result concerns certain metabolic indicators, rather than a proven reduction in liver fat. In the group that took ginger, insulin and HOMA-IR decreased compared to baseline, with P-values of 0.002 and 0.004, respectively. A P-value indicates how compatible a result is with the hypothesis of no statistical difference; it does not, on its own, measure the clinical utility of the effect.

In the same group, HDL cholesterol—often referred to as "good" cholesterol—improved, as did systolic and diastolic blood pressure. The reported P-values were 0.01 for HDL, 0.02 for systolic blood pressure, and less than 0.0001 for diastolic. However, both the ginger group and the placebo group showed reductions in body mass index, circumferences, and transaminases. Furthermore, inflammatory markers and FibroScan estimates of steatosis did not change significantly. The study does not report evidence of regression of hepatic steatosis.

The research is relevant because it considers a population with two conditions that often coexist: type 2 diabetes and fat accumulation in the liver. Insulin resistance means that muscles, liver, and adipose tissue respond less effectively to insulin; an estimated improvement in this could be consistent with a more favorable metabolic profile.

However, the value of the study is limited. Ginger was evaluated as a supplement and not as a substitute for diet, physical activity, medication, or clinical monitoring. The lack of change in instrumental liver indices serves as a reminder that a signal regarding insulin or blood pressure does not automatically equate to a structural benefit for the liver.

Three months is a short period to establish whether a metabolic change persists or alters the progression of liver disease. Furthermore, the sample size of 76 people limits the precision of the estimates and the possibility of applying them to all people with type 2 diabetes.

The study does not demonstrate that ginger cures hepatic steatosis, or prevents fibrosis, cirrhosis, or cardiovascular events. It also does not demonstrate that the observed variations depend on a specific compound in ginger or that the same regimen is appropriate outside of the experimental context. FibroScan is useful for non-invasive monitoring, but it does not replace all the information obtainable through clinical and, when indicated, histological evaluation. The lack of variations in FibroScan indices therefore requires a cautious interpretation.

A meta-analysis by Zhou and colleagues pooled four randomized trials involving 177 adults with non-alcoholic fatty liver disease. The overall result supported an improvement in alanine aminotransferase, total cholesterol, LDL cholesterol, and HOMA-IR compared to placebo [1]. This strengthens the chain linking ginger to metabolic and liver stress indicators, in line with the insulin signals observed by Ghoreishi. The level of confirmation is low-to-moderate: the included studies were few, short, and used different preparations; furthermore, the synthesis does not prove an effect on fibrosis or clinical outcomes.

A trial by Kamari and colleagues involved 160 children with obesity and fatty liver disease, divided into four groups for 12 weeks. The combination of ginger and an anti-inflammatory diet was associated with improvements in glycemia, liver enzymes, lipids, inflammation, and estimated steatosis [2]. This indirectly supports the hypothesis that a nutritional intervention with ginger can act on multiple metabolic indicators. However, it does not confirm the isolated effect in adults with diabetes: age, clinical context, and dietary co-intervention differ.

A randomized trial by Rafie and colleagues, conducted on 46 adults with non-alcoholic fatty liver disease over 12 weeks, found reductions in fasting glycemia, HOMA-IR, alanine aminotransferase, and certain markers in the ginger group. However, it did not find significant differences between groups regarding the degree of steatosis, fatty liver index, blood pressure, HDL, triglycerides, aspartate aminotransferase, and various inflammatory markers [3]. This result is directly relevant: it confirms that some metabolic signals can change, but indicates that the effects are not uniform and that improvements in blood tests do not prove a reduction of fat in the liver. The sample size was small, and all participants received guidance on diet and physical activity, factors that can attenuate the differences.

No directly conflicting evidence of sufficient relevance was identified beyond these inconsistent outcomes; this does not prove the absence of contrary results.